News

in the news

Derm-Biome Pharmaceuticals to develop skincare treatment that promotes skin health and longevity

August 13, 2024

Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding

May 8, 2024

Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects.

April 17, 2024

Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases

February 27, 2024

Derm-Biome Pharmaceuticals Announces Collaboration with Massachusetts General Hospital in Skin Cancer Study

November 28, 2023

Derm-Biome Pharmaceuticals to Present at the 2023 OBIO Investment Summit on February 10, 2023

February 7, 2023

Derm-Biome Pharmaceuticals’ Multi-Target Topical Drug Produces Positive Results in Preclinical Study in Acne

January 10, 2023

Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole

September 16, 2021

Derm-Biome Pharmaceuticals, Inc. files a US provisional patent for a new generation of natural product-based derivatives and their uses for treating chronic inflammatory skin conditions

June 28, 2021

Derm-Biome Pharmaceuticals, Inc. adds skin disease and microbiome specialists Drs. Youwen Zhou and Andy Sham to Its Newly Created Scientific Advisory Board

June 21, 2021

Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis

October 6, 2020

Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases

July 2, 2020

Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis

March 23, 2020

Skin health startup Derm-Biome Pharmaceuticals, Inc. to receive funding from the Government of Canada

July 9, 2019

Derm-Biome Pharmaceuticals Inc Seeks Collaborators To Test Promising Anti-Tumor Compound On Skin Cancer In Dogs Cats And Horses.

March 20, 2019

Derm-Biome Pharmaceuticals Inc. announces an exciting collaboration with Harvard Medical School

February 22, 2019

Derm-Biome Pharmaceuticals Inc. commences testing its proprietary compounds on skin microbiome targets.

October 26, 2018

Novelix Pharmaceuticals – Company Overview

October 23, 2009

Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio

December 1, 2008